NICE
NICE ‘surprised’ at downgrading of its role
November 5, 2010Sales and Marketing Andrew Dillon, GP prescribing deicisions, NICE, QALY, incremental cost-effectiveness ratio, value-based pricing
NICE received no warning that its health technology assessment role is to be downgraded, the watchdog’s head has admitted. In …
Don’t replace NICE with another ‘misguided experiment’
November 5, 2010Sales and Marketing NHS, NICE, Stockholm Network, medicines access, risk-sharing
Replacing NICE with a similar system would be detrimental to UK healthcare, according to the Stockholm Network, which further warns …
NICE refuses cancer drugs Arzerra, Torisel and Levact
October 27, 2010Sales and Marketing Arzerra, GSK, NICE, Napp Pharmaceuticals, Pfizer, Torisel, Treanda, cancer drugs
NICE has refused to recommend a trio of cancer drugs for NHS use – but in two cases says this …
£600m confirmed for three year Cancer Drugs Fund
October 27, 2010Sales and Marketing Cancer, Cancer Drugs Fund, NHS, NICE, cancer drugs, value-based pricing
The NHS will get the extra money it was promised to improve patient access to cancer medicines not backed by …
Minister confirms NICE will be sidelined in drug evaluation
October 26, 2010Sales and Marketing Andrew Lansley, Lord Howe, NICE, PPRS, medicines pricing, value-based pricing
A health minister has confirmed NICE will be “moved” from its current central role in health technology assessment to make …
NICE needs narrower focus, says ABPI
October 20, 2010Sales and Marketing ABPI, NICE, value
NICE’s remit should be changed to give it a greater focus on the value of innovation, according to UK pharma …
NICE rejects GSK Tyverb appeal
October 14, 2010Sales and Marketing GlaxoSmithKline, NICE, Tyverb
NICE’s independent appeal board has ruled the UK drug’s watchdog did not exceed its powers when issuing guidance on GlaxoSmithKline’s …
NICE unmoved on Takeda bone cancer drug
October 13, 2010Sales and Marketing Mepact, NICE, Takeda
NICE has refused to recommend Takeda’s Mepact because of its “exceptionally high cost” and the “substantial uncertainty” about the osteosarcoma …
Battle for Alzheimer’s drugs finally over
October 8, 2010Sales and Marketing Alzheimer's, Aricept, NICE
NICE is to allow wider access to Alzheimer’s disease treatments, ending an epic five year battle for access to the …
NICE announces change of heart on Alzheimer’s
October 7, 2010Sales and Marketing Alzheimer's, Aricept, Ebixa, Exelon, NICE, Reminyl
NICE is set to update its guidance on treatments for Alzheimer´s disease, widening access to four drugs. The draft guidance …
National Institute for health and Clinical Excellence (NICE)
October 1, 2010NICE, National Institute for health and Clinical Excellence
The National Institute for health and Clinical Excellence (NICE) is a UK cost-effectiveness body that assesses a drug’s cost against …
New Herceptin data sways NICE
September 30, 2010Sales and Marketing Herceptin, NICE, Roche
NICE is now minded to approve Roche’s Herceptin for patients with metastatic gastric cancer after receiving new efficacy data from …
Pay people to be healthy, say NICE advisors
September 28, 2010NHS, NICE, public health
The NHS should use financial incentives to encourage people to make healthier lifestyle changes, according to NICE’s Citizen’s Council. The …
GSK’s leukaemia drug rejected by NICE
September 16, 2010Sales and Marketing Arzerra, GSK, NHS, NICE
GSK’s leukaemia treatment Arzerra has been rejected by NICE, which says the drug does not represent good value for the …
NICE won’t approve Abilify without more data
September 13, 2010Sales and Marketing Abilify, BMS, NICE
NICE is unlikely to approve Bristol-Myers Squibb’s schizophrenia drug Abilify unless the company can provide more data on its clinical …
